California Paid Clinical Trials

A listing of 5607 clinical trials in California actively recruiting volunteers for paid trials and research studies in various therapeutic areas.

Home

All Clinical Trials

California

Show Filters

Match to Clinical Trials

Access to cutting-edge treatments

Latest clinical trials

Find trials in your area

Start Matching

Filter by Location

Filter by Age

California is currently home to 5607 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Los Angeles, San Francisco, San Diego and Sacramento. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.

Featured Trial

Paid Clinical Studies Nationwide

Recruiting

Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.

Conditions:

Healthy

Healthy Volunteer Study

Learn More

* Compensation for time may be available

Featured Offer

Lose Weight with GLP-1 Medications

Recruiting

Policy Lab has partnered with OnlineSemaglutide.org to offer trusted access to semaglutide and other GLP-1 medications, including generic alternatives to Ozempic® and Wegovy®.

GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.

As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.

Conditions:

Overweight

Overweight and Obesity

Obesity

Weight Loss

Morbid Obesity

Learn More

Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR Variant

NCT06563895

Recruiting

Transthyretin amyloidosis (ATTR) is a disease where the normally occurring transthyretin (TTR) protein falls apart and forms amyloid, a sticky plaque- like substance that accumulates in different organs in the body and can cause damage to the organ. There are two ways that the TTR protein can fall apart. One way occurs as a person ages, where the normal TTR protein can fall apart and form amyloid that may no longer be sufficiently cleared by the body. This type of ATTR is known as wild-type ATTR... Read More

Gender:

ALL

Ages:

Between 18 years and 75 years

Trial Updated:

06/02/2025

Locations: Stanford University, Stanford, California

Conditions: Amyloidosis, Amyloid Cardiomyopathy, Transthyretin Amyloidosis, Cardiomyopathies, Heart Diseases, Polyneuropathies

Learn More ›

Study to Evaluate the Safety and Efficacy of CSB-001 Ophthalmic Solution 0.1% in Subjects With Limbal Stem Cell Deficiency

NCT06452316

Recruiting

This study will enroll subjects with qualifying limbal stem cell deficiency (LSCD). All subjects will receive CSB-001 investigational drug in either one or both study eyes. The study is comprised of two identical phases (Dosing Phase I and II) of test article dosing separated by a 31- to 40-day period, the Dosing Holiday, where no test article is administered. Dosing Phase II is followed by an observational, noninterventional phase (Observation Phase).

Gender:

ALL

Ages:

18 years and above

Trial Updated:

06/02/2025

Locations: Loma Linda University Eye Institute, Loma Linda, California

Conditions: Limbal Stem Cell Deficiency

Learn More ›

Integrating CHWs Into Prenatal Care for Maternal Smoking Cessation

NCT06438549

Recruiting

This develops a novel behavioral tobacco cessation program for pregnant smokers in San Bernardino County.

Gender:

FEMALE

Ages:

18 years and above

Trial Updated:

06/02/2025

Locations: Loma Linda University Medical Center, Loma Linda, California

Conditions: Tobacco Use, Tobacco Use Cessation, Tobacco Use in Childbirth

Learn More ›

INBRX-106 in Combination With Pembrolizumab in First-line PD-L1 CPS≥20 HNSCC

NCT06295731

Recruiting

This seamless phase 2/3 randomized controlled study will evaluate the efficacy and safety of the hexavalent OX40 agonist antibody INBRX-106 combined with the anti-PD-1 antibody pembrolizumab versus pembrolizumab (+ placebo in phase 3) as first-line treatment for patients with locally advanced recurrent or metastatic head and neck squamous cell carcinoma (R/M HSNSCC) incurable by local therapies, expressing PD-L1 with a combined proportion score (CPS) ≥20.

Gender:

ALL

Ages:

18 years and above

Trial Updated:

06/02/2025

Locations: City of Hope Medical Center, Duarte, California

Conditions: Head and Neck Squamous Cell Carcinoma (HNSCC)

Learn More ›

A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer

NCT06203210

Recruiting

This study was designed to compare the efficacy and safety of I-DXd with treatment of physician's choice in participants with relapsed small cell lung cancer (SCLC).

Gender:

ALL

Ages:

18 years and above

Trial Updated:

06/02/2025

Locations: Clinical Research Providence Medical Foundation, Fullerton, California

Conditions: Small Cell Lung Cancer

Learn More ›

The Effects of Fresh Mango Consumption on Cardiometabolic Outcomes in Free-living Individuals With Prediabetes

NCT06159543

Recruiting

The goal of this clinical trial is to test the effect of 12 weeks of 1.5 cups per day of fresh mango on glucose control, insulin resistance, lipids, inflammation, oxidation and body composition in individuals with prediabetes. The main questions it aims to answer are: * What is the effect of 1.5 cups per day of fresh mango over 12 weeks on indicators of glycemic control including fasting glucose and HgbA1c? * What is the effect of 1.5 cups per day of fresh mango over 12 weeks on fasting blood insulin and insulin resistance (HOMA-IR)? * What is the effect of 1.5 cups per day of fresh mango over 12 weeks on lipids including LDL-cholesterol, total cholesterol, HDL-cholesterol and triglycerides? * What is the effect of 1.5 cups per day of fresh mango over 12 weeks on oxidative stress including oxidized LDL-cholesterol and 8-iso-PGF2-alpha? * What is the effect of 1.5 cups per day of fresh mango over 12 weeks on markers of inflammation including c-reactive protein, e-selectin, ICAM, VCAM, TNF-alpha and IL-beta? * What is the effect of 1.5 cups per day of fresh mango over 12 weeks on percent body fat, fat mass, and lean mass? Participants will be asked to: * Consume 1.5 cups of mango per day for 12 weeks, take a 4 to 8 week break, and then avoid consuming mangos for 12 weeks * Attend a prerandomization clinic prior to study * Attend three (3) clinics where blood will be drawn during weeks 0, and 12 of the first phase and last week of the second phase of the study * Attend eight (8) clinics where anthropometric measurements (height, weight, body composition) will be conducted and interaction with study clinicians will occur during weeks 0, 4, 8, 12 of each phase of the study * Complete questionnaires and surveys in person and remotely, including six (6) 24-hour dietary recalls. Researchers will compare the 12 weeks participants consume mango to the 12 weeks the participants are not consuming mango to see if there are differences in glycemic indicators, insulin resistance, lipids, inflammation, oxidation and body composition between the two time periods. Read Less

Gender:

ALL

Ages:

Between 40 years and 60 years

Trial Updated:

06/02/2025

Locations: Nutrition Research Center, School of Public Health, Loma Linda University, Loma Linda, California

Conditions: Hyperglycemia, Dyslipidemias, Insulin Resistance, Inflammation, Oxidative Stress

Learn More ›

A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab for Neoadjuvant/Adjuvant Treatment of Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer

NCT06112379

Recruiting

This is a Phase III, 2-arm, randomised, open-label, multicentre, global study assessing the efficacy and safety of neoadjuvant Dato-DXd plus durvalumab followed by adjuvant durvalumab with or without chemotherapy compared with neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab with or without chemotherapy in participants with previously untreated TNBC or hormone receptor-low/HER2-negative breast cancer.

Gender:

ALL

Ages:

18 years and above

Trial Updated:

06/02/2025

Locations: Research Site, Bakersfield, California

Conditions: Breast Cancer

Learn More ›

Pasireotide s.c. in Patients With Post-Bariatric Hypoglycaemia

NCT05928390

Recruiting

The Total duration of trial participation for each participant with post-bariatric hypoglycemia will be a maximum of 59 weeks, with the following duration of trial periods * 19 weeks for the Core Phase. It is composed of: * a Screening period: a maximum of 3 weeks * a Run-in period (no treatment): 4 weeks * a Blinded Treatment Phase: 12 weeks * 36 weeks Extension Phase = an open-label Treatment period * 4 weeks for the safety follow-up period (without any treatment).

Gender:

ALL

Ages:

18 years and above

Trial Updated:

06/02/2025

Locations: Stanford University School of Medicine, Endocrinology, 800 Welch Road,, Palo Alto, California

Conditions: Post-Bariatric Hypoglycemia

Learn More ›

Study of Apalutamide With Carotuximab in Metastatic, Castration-Resistant Prostate Cancer

NCT05534646

Recruiting

This is an open-label, multi-site study of apalutamide with carotuximab in patients who have progressed on androgen receptor signaling inhibitor (ARSI) therapy. This study will begin with a safety assessment in the first 10 subjects (part 1: Safety Lead-in). If the combination is deemed safe, the trial will proceed to the Phase II stage. The purpose of this study is to compare progression free survival (PFS) between patients receiving apalutamide and apalutamide + carotuximab using Response Eval... Read More

Gender:

MALE

Ages:

18 years and above

Trial Updated:

06/02/2025

Locations: City of Hope, Duarte, California

Conditions: Castration-resistant Prostate Cancer

Learn More ›

Study of Vorasidenib and Pembrolizumab Combination in Recurrent or Progressive IDH-1 Mutant Glioma

NCT05484622

Recruiting

Vorasidenib in combination with pembrolizumab in participants with recurrent or progressive isocitrate dehydrogenase-1 (IDH-1) mutant Glioma.

Gender:

ALL

Ages:

18 years and above

Trial Updated:

06/02/2025

Locations: University of California, Los Angeles (Site: 840113), Los Angeles, California

Conditions: Astrocytoma, Oligodendroglioma

Learn More ›

CONVERGE Post-Approval Study (PAS)

NCT05393180

Recruiting

The primary objective of CONVERGE PAS is to evaluate clinical outcomes (peri-procedural and long-term) in a cohort of patients treated during commercial use of the EPi-Sense® Guided Coagulation System or EPi-Sense ST™ Coagulation System to treat symptomatic long-standing persistent atrial fibrillation (AF) patients who are refractory or intolerant to at least one Class I and/or III AAD.

Gender:

ALL

Ages:

Between 18 years and 80 years

Trial Updated:

06/02/2025

Locations: Hoag Memorial Hospital Presbyterian, Newport Beach, California

Conditions: Chronic Atrial Fibrillation

Learn More ›

A Study to Determine the Efficacy and Safety of Tividenofusp Alfa (DNL310) vs Idursulfase in Pediatric and Young Adult Participants With Neuronopathic (nMPS II) or Non-Neuronopathic Mucopolysaccharidosis Type II (nnMPS II)

NCT05371613

Recruiting

This is a Phase 2/3, multiregional, two-arm, double-blind, randomized, active (standard-of-care)-controlled study of the efficacy and safety of tividenofusp alfa (DNL310), an investigational central nervous system (CNS)-penetrant enzyme-replacement therapy (ERT) for mucopolysaccharidosis type II (MPS II). Participants may also qualify to enter an open-label treatment phase with DNL310 or idursulfase based on pre-specified criteria.

Gender:

ALL

Ages:

Between 2 years and 26 years

Trial Updated:

06/02/2025

Locations: UCSF Benioff Children's Hospital Oakland, Oakland, California

Conditions: Mucopolysaccharidosis II

Learn More ›

Kaiser Permanente houses over 6,000 physicians in southern California and it is also one of the largest research centers on the state. On its clinical trial division, Kaiser Permanente conducts clinical trials of almost every specialty funded by pharmaceutical companies, government, and foundations.

The Cedars-Sinai Medical Center located in Los Angeles is one of the largest research centers owned and operated by a private hospital in the United States. Focusing on biomedical, cancer, and heart research among other specialties, you can find almost any type of clinical trials for both health and non-healthy volunteers at the research division of Cedar-Sinai Medical Center.

There are around 100,000 clinical trials happening every year across the United States about almost every condition out there. While most clinical trials are testing drugs or medical devices there are also many behavioral and observational trials going on at any point in time. Many paid research studies are held at these California locations.

Clinical trials are incredibly important for making new medical and scientific discoveries, finding new and better methods for diagnosing medical conditions early, testing new interventions, and even developing safer and more effective surgical procedures.

In order for all these discoveries to me made available to the general population they need to go through years of rigorous testing both in healthy and non-healthy volunteers. During those years, medical professionals follow a protocol that has been previously approved by the FDA or other regulatory agency to test the effectiveness and safety of their discovery.

Other people choose to participate in a clinical trial because they feel it is a good way to contribute to the advancement of medical knowledge and that their participation can help many people in the future. The following lists of trials are broken down by condition, and to find a specific clinical trial in your area click through to clinicaltrials.gov.